290 related articles for article (PubMed ID: 7561024)
1. Exogenous hepatitis B surface antigen particles processed by dendritic cells or macrophages prime murine MHC class I-restricted cytotoxic T lymphocytes in vivo.
Böhm W; Schirmbeck R; Elbe A; Melber K; Diminky D; Kraal G; van Rooijen N; Barenholz Y; Reimann J
J Immunol; 1995 Oct; 155(7):3313-21. PubMed ID: 7561024
[TBL] [Abstract][Full Text] [Related]
2. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.
Wild J; Grusby MJ; Schirmbeck R; Reimann J
J Immunol; 1999 Aug; 163(4):1880-7. PubMed ID: 10438922
[TBL] [Abstract][Full Text] [Related]
3. Processing of exogenous heat-aggregated (denatured) and particulate (native) hepatitis B surface antigen for class I-restricted epitope presentation.
Schirmbeck R; Böhm W; Melber K; Reimann J
J Immunol; 1995 Nov; 155(10):4676-84. PubMed ID: 7594467
[TBL] [Abstract][Full Text] [Related]
4. Induction of antitumor immunity using bone marrow-generated dendritic cells.
Porgador A; Snyder D; Gilboa E
J Immunol; 1996 Apr; 156(8):2918-26. PubMed ID: 8609412
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes.
Bachmann MF; Lutz MB; Layton GT; Harris SJ; Fehr T; Rescigno M; Ricciardi-Castagnoli P
Eur J Immunol; 1996 Nov; 26(11):2595-600. PubMed ID: 8921944
[TBL] [Abstract][Full Text] [Related]
6. Enhancing the immunogenicity of exogenous hepatitis B surface antigen-based vaccines for MHC-I-restricted T cells.
Schirmbeck R; Reimann J
Biol Chem; 1999 Mar; 380(3):285-91. PubMed ID: 10223330
[TBL] [Abstract][Full Text] [Related]
7. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
[TBL] [Abstract][Full Text] [Related]
8. Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo.
Schirmbeck R; Melber K; Kuhröber A; Janowicz ZA; Reimann J
J Immunol; 1994 Feb; 152(3):1110-9. PubMed ID: 8301120
[TBL] [Abstract][Full Text] [Related]
9. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL.
Kern DE; Klarnet JP; Jensen MC; Greenberg PD
J Immunol; 1986 Jun; 136(11):4303-10. PubMed ID: 2422280
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow.
Yang S; Darrow TL; Vervaert CE; Seigler HF
Cell Immunol; 1997 Jul; 179(1):84-95. PubMed ID: 9259775
[TBL] [Abstract][Full Text] [Related]
11. DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors.
Schirmbeck R; Böhm W; Reimann J
J Immunol; 1996 Oct; 157(8):3550-8. PubMed ID: 8871655
[TBL] [Abstract][Full Text] [Related]
12. Role of dendritic cells in the priming of CD4+ T lymphocytes to peptide antigen in vivo.
Levin D; Constant S; Pasqualini T; Flavell R; Bottomly K
J Immunol; 1993 Dec; 151(12):6742-50. PubMed ID: 7903097
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors.
Gabrilovich DI; Nadaf S; Corak J; Berzofsky JA; Carbone DP
Cell Immunol; 1996 May; 170(1):111-9. PubMed ID: 8665591
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of thymus-independent type 2 antigens on MHC class II-restricted antigen presentation: comparative analysis of carbohydrate structures and the antigen presenting cell.
González-Fernández M; Carrasco-Marín E; Alvarez-Domínguez C; Outschoorn IM; Leyva-Cobián F
Cell Immunol; 1997 Feb; 176(1):1-13. PubMed ID: 9070312
[TBL] [Abstract][Full Text] [Related]
15. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of cytotoxic T lymphocyte development by a minor stimulating locus-induced suppressor cascade that involves Lyt-1+ suppressor T cells, IA- macrophages, and their factors.
Chow KP; Battisto JR
J Immunol; 1988 Feb; 140(4):1005-13. PubMed ID: 2963857
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the functional properties of murine dendritic cells generated in vivo with Flt3 ligand, GM-CSF and Flt3 ligand plus GM-SCF.
Daro E; Butz E; Smith J; Teepe M; Maliszewski CR; McKenna HJ
Cytokine; 2002 Feb; 17(3):119-30. PubMed ID: 11895330
[TBL] [Abstract][Full Text] [Related]
18. Failure or success in the restoration of virus-specific cytotoxic T lymphocyte response defects by dendritic cells.
Kast WM; Boog CJ; Roep BO; Voordouw AC; Melief CJ
J Immunol; 1988 May; 140(9):3186-93. PubMed ID: 2834454
[TBL] [Abstract][Full Text] [Related]
19. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells.
Bianchi R; Grohmann U; Belladonna ML; Silla S; Fallarino F; Ayroldi E; Fioretti MC; Puccetti P
J Immunol; 1996 Aug; 157(4):1589-97. PubMed ID: 8759743
[TBL] [Abstract][Full Text] [Related]
20. Induction of CTL in vivo by major histocompatibility complex class I-peptide complexes covalently associated on the cell surface.
Anjuère F; Horvath C; Cerottini JC; Luescher IF
Eur J Immunol; 1995 Jun; 25(6):1535-40. PubMed ID: 7614979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
